Sanofi - ADR (SNY) News
Filter SNY News Items
SNY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNY News Highlights
- 500 - Internal server error
- Over the past 25 days, the trend for SNY's stories per day has been choppy and unclear. It has oscillated between 1 and 30.
- The most mentioned tickers in articles about SNY are SA, GSK and REGN.
Latest SNY News From Around the Web
Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.
Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA RejectionSanofi SA’s (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia without a recent history of blood transfusion. Topline results will be presented at the European Hematology Association 2021 Congress. The results of the 42-subject study showed that sutimlimab was able to reduce the destruction of red blood cells (haemolysis) seen in patients with CAD within one week of |
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemiaNew pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with cold agglutinin disease, a serious and chronic autoimmune hemolytic anemia Phase 3 data from the CADENZA study met the primary composite endpoint with statistical significance; secondary endpoint data were clinically meaningfulFindings provide further evidence that sutimlimab results in rapid inhibition of C1-activ |
The next generation Covid-19 vaccines seeking a slice of the marketBioNTech/Pfizer and Moderna, the pandemic’s mRNA-based vaccine frontrunners, have already booked billions of dollars in revenue, which they are using to boost production, sign new contracts and entrench their positions. Likewise, Oxford/AstraZeneca and Johnson & Johnson have been rolling out their cheaper and easier to transport shots for months, while Chinese and Russian-made vaccines dominate in several markets. Large pharma companies like Sanofi and GSK are hoping to shake off their image as laggards, while start-ups such as Novavax, CureVac and Valneva see opportunities to satisfy unmet needs. |
Sanofi SA (SNY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)Sanofi SA (SNY) Goldman Sachs 42nd Annual Global Healthcare Conference June 9, 2021 2:10 PM ET Company Participants John Reed - EVP, Global Head of Research & Development Conference Call Participants Keyur Parekh - Goldman Sachs Presentation Keyur Parekh Good morning, good afternoon and good evening, and thank you all... |
U.S. response to COVID-19 has a greater list of failures than accomplishments: ExpertChris Meekins,Raymond James Healthcare Policy Analyst, joins Yahoo Finance Live to break down what went well and poorly during the COVID-19 pandemic and how to better prepare for possible future pandemic. |
Translate Bio gets $50M mRNA vaccine program milestone payment from Sanofi PasteurTranslate Bio (TBIO) announces that it has received a $50M milestone payment from Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), under the collaboration related to its influenza mRNA vaccine program.The payment was triggered following the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur’s Phase 1... |
Elevation Oncology Files for $100M IPOElevation Oncology has filed to raise $100 million in an IPO. See SEC prospectus here. Proceeds will be used to support the development of seribantumab that failed multiple trials at Merrimack Pharmaceuticals Inc (NASDAQ: MACK) before being picked up by Elevation and repositioned as a treatment for solid tumors harboring an NRG1 fusion. The anti-HER3 antibody failed multiple mid-phase trials, causing Sanofi SA (NASDAQ: SNY) to return the rights to the drug and ultimately leading to Merrimack off |
Sanofi launches its new global employee share ownership planSanofi launches its new global employee share ownership plan PARIS - June 7, 2021 - Sanofi today launches Action 2021, its global employee share ownership plan, open to 92,000 employees in 73 countries. The program, similar to programs carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company. "The record level of employee participation in last |
Jefferies Stick to Their Buy Rating for Sanofi By Investing.comJefferies Stick to Their Buy Rating for Sanofi |
Sanofi (SNY) Presents At 2021 American Society of Clinical Oncology Annual Meeting - SlideshowThe following slide deck was published by Sanofi in conjunction with this event.... |